Tarloxotinib: Phase II started

Threshold began an open-label, U.S. and Australian Phase II trial to evaluate 150 mg/m 2 IV tarloxotinib on days 1, 8, 15 and 22 of a 28-day cycle in up to 68 patients. Threshold has exclusive, worldw...